Effects Of Rosiglitazone Maleate And Simvastatin On Fasting Serum C-reactive Protein In Patients With Insulin Resistance

Objective: To investigate the effects of rosiglitazone maleate and simvastatin on fasting serum C-reactive protein in patients with insulin resistanceMethods: The study was a randomized block design including 51 subjects with insulin resistance (fasting serum insulin>16.8mIU/L) .They were divided into 3 groups, i.e. rosiglitazone maleate (R) (17 cases), simvastatin (S) (17 cases) and control (C) (17 cases) groups.The subjects of group R were treated with rosiglitazone maleate 4mg daily. The subjects of group S were given simvastatin 20mg daily, and group C were not treated.They were followed 14 days.Fasting serum interleukin-6 (IL-6), tumor necrosis factor-a (TNF- a ) and CRP were measured at day 0 and at day 15. Results: At the end of the study, log (CRP) levels weresignificantly lower in group R, S than baseline data, while log(CRP) level was slightly higher in group C using t test (t=5.430, p< 0.001, t=2.827, p< 0.012, and t=0.122, p=0.904, respectively) .At day 15, log (CRP) was significantly lower in patients on rosiglitazone maleate when compared with simvastatin (p<0.05) using q test. In addition, there was no significant effect on either IL-6 or TNF- a . Conclusions : Rosiglitazone maleate and simvastatin significantly decreased levels of CRP in patients with insulin resistance, whilst the effect of simvastatin was likely smaller compared with that of rosiglitazone maleate.